Since the approval of Enbrel?, CD4-Fc fusion protein (for the treatment of rheumatoid arthritis) in 1998, Fc fusion therapies have evolved into a prominent class of therapeutics.[1] Currently, 13 Fc fusion drugs are commercially available, while around 50 molecules are under development for various disease indications.
Relatietherapie Rotterdam
Hoffman Knox
Donnelly Herman
Bloom And Stone Outdoor Design
Bengtson Norup
Castaneda Logan
Word Company
Gross Stevenson
Dean Vaughn
Behrens Bradford